Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The investigators designed a compassionate basis phase II study for refractory/relapsed
mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation
of overall response and time to relapse. Other goals to consider are toxicity and time to new
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Latin American Cooperative Onco-Haematology Group - Peru